Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients
Status:
Unknown status
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The aim of present study is to evaluate if the addition of Aprepitant to multiple doses of
palonosetron IV enhances the efficacy of multiple doses of palonosetron IV alone, in
preventing CINV in AML or High risk MDS patient, treated with multiple days chemotherapy.